The Impact of CPAP on Comorbid Conditions [AAST Annual Meeting Preview]
Vikas Jain, MD, has taken on the challenging task of separating fact from opinion with regard to the impact of CPAP on comorbidities such as cardiovascular risk.
He became interested in the topic after recent studies, such as the Sleep Apnea Cardiovascular Endpoints (SAVE) trial, published unexpected results. (The SAVE trial found that CPAP plus usual care, versus usual care alone, did not prevent cardiovascular events in patients with moderate-to-severe obstructive sleep apnea and established cardiovascular disease.)1
“When you look at the evidence and separate the facts from opinion, it may be eye opening and may impact the way we tend to approach treating sleep-disordered breathing,” Jain says.
Jain will be presenting on this topic at the 2018 AAST Annual Meeting, to be held Sept 28-30 in Indianapolis. His breakout session is entitled “CPAP—All Pain and No Gain?”
Jain hopes his session will “spark a lively discussion and that individuals will leave with a broader perspective on treating sleep disordered breathing.”
Sree Roy is editor of Sleep Review.
1. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med. 2016 Sep 8;375(10):919-31.
from Sleep Review http://www.sleepreviewmag.com/2018/08/impact-cpap-comorbid-conditions-aast-annual-meeting-preview/